Journals / Respiratory Case Reports / 2021 / Cilt: 10 - Sayı: 3

A Case with Avascular Bone Necrosis Developing as a Complication of COVID-19 Treatment

COVID-19 tedavisi Komplikasyonu Olarak Avasküler Kemik Nekrozu Gelişen Olgu

Pages
220–223
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present here a case in which avascular bone necrosis developed as a result of long-term steroid use for the treatment of COVID-19.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:As our knowledge and experience of COVID-19 increases, our treatment approaches may change.
📊
Key Findings & Data:For patients with respiratory failure due to COVID-19 disease, the disease table can be better controlled with systemic glucocorticoids, and mortality rates and hospitalization periods can also be reduced.
💡
Conclusion & Impact:We present here a case in which avascular bone necrosis developed as a result of long-term steroid use for the treatment of COVID-19.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

As our knowledge and experience of COVID-19 increases, our treatment approaches may change. For patients with respiratory failure due to COVID-19 disease, the disease table can be better controlled with systemic glucocorticoids, and mortality rates and hospitalization periods can also be reduced. Steroid therapy can be applied for the long-term, especially in cases with organized pneumonia, and patients can be discharged from hospital with maintenance treat- ment. Complications have been noted in patients in the post-COVID period resulting from the use of glucocorticoids. While mostly bacterial and fungal lung infections are seen, another side-effect of gluco- corticoids is their negative effect on bone metabolism. We present here a case in which avascular bone necrosis developed as a result of long-term steroid use for the treatment of COVID-19.

Özet

COVID-19 hastalığı ile ilgili bilgilerimiz ve deneyimle- rimiz arttıkça tedavi yaklaşımlarımız da değişebilmek- tedir. COVID-19 hastalığına bağlı olarak solunum yetmezliği gelişmiş olan hastalarda sistemik glukokor- tikoidler ile hastalık tablosu daha iyi kontrol altına alınabilmekte ve mortalite oranları ile hastane yatış süreleri de azalmaktadır. Özellikle organize pnömoni gelişmiş olgularda steroid tedavisi uzun süreli olabil- mekte ve hastalar idame tedavisi ile taburcu olabil- mektedirler. Bununla beraber, hastalarda glukokorti- koid kullanımına bağlı olarak postcovid dönemde komplikasyonlar da görebilmekteyiz. Daha çok bak- teriyel ve mantara bağlı akciğer enfeksiyonları görü- lürken, glukokortikoidlerin diğer bir yan etkisi de kemik metabolizması üzerine olan olumsuz etkileridir. Burada, COVID-19 nedeni ile uzun süreli steroid kullanımı sonucu avasküler kemik nekrozu gelişen olguyu sunduk

🔖

Cite This Article

Yılmam, İ., Edis, E. Ç., Çopuroğlu, C., Ustabaşıoğlu, F. E., Kaya, B. S. (2022). A Case with Avascular Bone Necrosis Developing as a Complication of COVID-19 Treatment. Respiratory Case Reports, Cilt: 10 - Sayı: 3, 220–223. https://ajindex.com/articles/588913

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020
  2. [CrossRef] 2. WHO. Coronavirus disease (COVID-2019) situation re- ports. 2020. 3. WHO. Clinical management of COVID-19 interim gui- dance. 27 May 2020. 4. Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, Zhong N. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 2006
  3. [CrossRef] 5. RECOVERY Collaborative Group, Horby P, Lim WS, Em- berson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021
  4. [CrossRef] 6. Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid- induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007
  5. [CrossRef] 7. Canalis E, Mazziotti G, Guistina A, Bilezikian JP. Gluco- corticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis Int 2007
  6. [CrossRef] 8. Devogelaer JP. Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. Rheum Dis Clin North Am 2006
  7. [CrossRef] 9. McKee MD, Waddell JP, Kudo PA, Schemitsch EH, Rich- ards RR. Osteonecrosis of the femoral head in men fol- lowing short-course corticosteroid therapy: a report of 15 cases. CMAJ 2001
  8. Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, et al. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and cal- cium homeostasis. J Rheumatol 2007
  9. Kamal D, Traistaru R, Alexandru DO, Kamal CK, Pirici D, Pop OT, et al. Morphometric findings in avascular necro- sis of the femoral head. Rom J Morphol Embryol 2012
  10. 53(3 Suppl):763-7. 12. Özçakı Ş. Kalçanın avasküler nekrozu. Türk Fiz Tıp Rehab Derg 2009
  11. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical−therapeutic staging proposal. J Heart Lung Transplant 2020
  12. [CrossRef] 14. WHO/2019-nCoV/Corticosteroids/2020.1. 15. T.C. Sağlık Bakanlığ ı COVID-19 (SARS-CoV-2 En- feksiyonu) Ağ ır pnömoni, ARDS, sepsis ve septik şok yönetimi. 7 Kasım 2020. 16. Auyeung TW, Lee JSW, Lai WK, Choi CH, Lee HK, Lee JS, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect 2005
  13. [CrossRef] 17. Xie L, Liu Y, Fan B,